Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

References

• GattaGRossiSCapocacciaRCancer burden estimates and forecasts: uses and cautionsTumori201399343944324158074
   PubMed Web of Science ®Google Scholar
• ChouaidCAtsouKHejblumGVergnenegreAEconomics of treatments for non-small cell lung cancerPharmacoeconomics200927211312519254045
   PubMed Web of Science ®Google Scholar
• IslaDGonzález-RojasNNievesDBrosaMFinnernHWTreatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panelClin Transl Oncol201113746047121775273
   PubMed Web of Science ®Google Scholar
• NeubauerMAHovermanJRKolodziejMCost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community settingJ Oncol Pract201061121820539725
   PubMedGoogle Scholar
• LewisJRLipworthWLKerridgeIHDayROThe economic evaluation of personalised oncology medicines: ethical challengesMed J Aust2013199747147324099207
   PubMed Web of Science ®Google Scholar
• BesseBAdjeiABaasPPanel Members2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseAnn Oncol20142581475148424669016
   PubMed Web of Science ®Google Scholar
• BrownTBolandABagustAGefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancerHealth Technol Assess201014Suppl 2717921047494
   PubMed Web of Science ®Google Scholar
• BongersMLCoupéVMJansmaEPSmitEFUyl-de GrootCACost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic reviewPharmacoeconomics2012301173422201521
   PubMed Web of Science ®Google Scholar
• BrownTPilkingtonGBagustAClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluationHealth Technol Assess201317311278
   Web of Science ®Google Scholar
• NeymarkNLianesPSmitEFvan MeerbeeckJPEconomic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancerPharmacoeconomics200523111155116616277550
   PubMed Web of Science ®Google Scholar
• ThongprasertSPermsuwanURuengornCCharoentumCChewaskulyongBCost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancerAsia Pac J Clin Oncol20117436937522151987
   PubMed Web of Science ®Google Scholar
• PimentelFLBhallaSLaranjeiraLGuerreiroMCost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancerLung Cancer200652336537116650499
   PubMed Web of Science ®Google Scholar
• NovelloSKielhornAStynesGItalian Lung Cancer Project InvestigatorsCost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in ItalyLung Cancer200548337938715893007
   PubMed Web of Science ®Google Scholar
• SchillerJTildenDAristidesMRetrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in EuropeLung Cancer200443110111214698544
   PubMed Web of Science ®Google Scholar
• KleinRMuehlenbeinCLiepaAMBabineauxSWielageRSchwartzbergLCost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancerJ Thorac Oncol20094111404141419786904
   PubMed Web of Science ®Google Scholar
• ShahMWinfreeKBPetersonPGruschkusSKEaddyMGreenMRCost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient settingLung Cancer201382112112723973203
   PubMed Web of Science ®Google Scholar
• TadaHMatsuiSKawaharaMHosoeSHamadaCFukushimaMEfficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experienceEur J Cancer Care (Engl)200817212012618302648
   PubMed Web of Science ®Google Scholar
• ManiadakisNFragoulakisVPallisAPrezerakosPGeorgouliasVEconomic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in GreeceLung Cancer200758227528117688969
   PubMed Web of Science ®Google Scholar
• HornLVisbalALeighlNBDocetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomicsDrugs Aging200724541142817503897
   PubMed Web of Science ®Google Scholar
• ReaumeMNLeighlNBMittmannNEconomic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)Lung Cancer201382111512023962449
   PubMed Web of Science ®Google Scholar
• Le LayKMyonEHillSComparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS systemEur J Health Econ20078214515117333088
   PubMed Web of Science ®Google Scholar
• ChouaidCLe CaerHLocherCGFPC 0504 TeamCost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)BMC Cancer201212130122817667
   PubMed Web of Science ®Google Scholar
• ChouaidCLe CaerHCorreRCost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)Clin Lung Cancer201314210310722682669
   PubMed Web of Science ®Google Scholar
• WangSPengLLiJA trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerPLoS ONE201383e5591723520448
   PubMed Web of Science ®Google Scholar
• HandorfEAMcElligottSVachaniACost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lungJ Oncol Pract20128526727423277762
   PubMedGoogle Scholar
• de Lima LopesGJrSegelJETanDSDoYKMokTFinkelsteinEACost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lungCancer201211841032103921792863
   PubMed Web of Science ®Google Scholar
• LeeVWSchwanderBLeeVHEffectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong KongHong Kong Med J201420317818624281768
   PubMed Web of Science ®Google Scholar
• DjalalovSBecaJHochJSCost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancerJ Clin Oncol201432101012101924567430
   PubMed Web of Science ®Google Scholar
• ChouaidCBorgetIVergnenegreATarget therapies in non-small-cell lung cancer management: no cost-effective strategies?J Clin Oncol Epub982014
   Web of Science ®Google Scholar
• AhnMJTsaiCMHsiaTCCost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and TaiwanAsia Pac J Clin Oncol20117Suppl 2223321585705
   PubMed Web of Science ®Google Scholar
• GoulartBRamseySA trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancerValue Health201114683684521914503
   PubMed Web of Science ®Google Scholar
• GiulianiGGrossiFde MarinisFWalzerSCost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in ItalyLung Cancer201069Suppl 1S11S1720727457
   PubMedGoogle Scholar
• ChienCRShihYCChun -RuCYa-ChenTSEconomic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)Clinicoecon Outcomes Res2012420120822870040
   PubMedGoogle Scholar
• BischoffHGHeigenerDFWalzerSNuijtenMCosts of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and GermanyLung Cancer20101S18S2320727458
   PubMedGoogle Scholar
• StanisicSBischoffHGHeigenerDFSocietal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Lung Cancer201069Suppl 1S24S3020727459
   PubMedGoogle Scholar
• KleinRWielageRMuehlenbeinCCost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancerJ Thorac Oncol2010581263127220581708
   PubMed Web of Science ®Google Scholar
• ZhuJLiTWangXGene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysisBMC Cancer20131313923360224
   PubMed Web of Science ®Google Scholar
• ZengXPengLLiJCost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care systemClin Ther2013351546523328269
   PubMed Web of Science ®Google Scholar
• ZengXLiJPengLEconomic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysisPLoS ONE201492e8888124586426
   PubMed Web of Science ®Google Scholar
• DicksonRBagustABolandAErlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisalPharmacoeconomics201129121051106221967156
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAErlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancerPharmacoeconomics2010281759220014878
   PubMed Web of Science ®Google Scholar
• NuijtenMJde Castro CarpeñoJChouaidCA cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer201276346547122153602
   PubMed Web of Science ®Google Scholar
• WalleserSRayJBischoffHMaintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeClinicoecon Outcomes Res2012426927523028234
   PubMedGoogle Scholar
• VergnenègreARayJAChouaidCCross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerClinicoecon Outcomes Res20124313722347803
   PubMedGoogle Scholar
• GreenhalghJMcLeodCBagustAPemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancerHealth Technol Assess201014Suppl 2333921047489
   PubMed Web of Science ®Google Scholar
• Matter-WalstraKJoergerMKühnelUSzucsTPestalozziBSchwenkglenksMCost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care systemValue Health2012151657122264973
   PubMed Web of Science ®Google Scholar
• SimondsNIKhouryMJSchullySDComparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospectsJ Natl Cancer Inst20131051392993623661804
   PubMedGoogle Scholar
• Uyl-de GrootCAMcDonnellJTen VeldeGRadiceDGroenHJCost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain modelTher Clin Risk Manag20062331732318360607
   PubMedGoogle Scholar